[Can one reconcile planning and innovation?].
Israël
L
L
Clinique universitaire de cancérologie, université Paris-XIII, CHU Avicenne, Bobigny, France.
D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use; D007376:Interleukin-2 / Q000627:therapeutic use; D009369:Neoplasms / Q000628:therapy*; D012107:Research Design
D007370:Interferon Type I; D007376:Interleukin-2
Peut-on concilier concertation et innovation?